Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy male and female subjects, 18 to 65 years of age. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and complete physical examination
Body mass index (BMI) 18 to 30 kg/m2
Females of child-bearing potential must agree to use two effective methods of contraception, including a barrier method and an intrauterine non-hormonal device (set in place at least 3 months before first dosing) for the duration of the study and at least 1 month after last dosing
Non-smoker for at least 90 days prior to screening
You may not be if
Pregnant or lactating females
History of drug abuse in the past 2 years, or suspicion of regular consumption of drugs of abuse, or positive result on drugs of abuse test
History of alcoholism in the past 2 years, or positive alcohol test
Positive for hepatitis B, hepatitis C or HIV infection
Systemic , topical, intranasal or inhaled corticosteroid therapy for more than 2 weeks within 3 months prior to screening
Participation in an investigational drug or device study within 90 days prior to screening
Clareo Health | A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
